(HLN) Haleon - Ratings and Ratios

Exchange: NYSE • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US4055521003

HLN: Toothpaste, Mouthwash, Vitamins, Supplements, Pain Relievers, Antacids

Haleon plc (NYSE: HLN) stands as a global leader in the consumer healthcare sector, emerging from the strategic separation of GSKs Consumer Healthcare business and Pfizers Consumer Healthcare joint venture in 2022. This reorganization positioned Haleon as an independent entity, leveraging a rich legacy tracing back to 1715, with a strong foundation in innovation and trusted brands.

The companys product portfolio is both extensive and diverse, addressing a wide array of consumer health needs. In oral health, Haleon commands a significant presence with brands like Sensodyne, known for its sensitivity relief, and Polident for denture care. Their offerings extend to dietary supplements, where Centrum and Emergen-C are household names, catering to the growing demand for health and wellness products.

Haleons over-the-counter (OTC) medications are a cornerstone of their business, providing relief for common ailments. Theraflu and Flonase are staples for respiratory issues, while Panadol and Advil are go-to solutions for pain management. Their digestive health offerings, including TUMS and ENO, underscore their commitment to addressing everyday health concerns.

Financially, Haleon presents an intriguing profile for investors. With a market capitalization exceeding $43 billion, the company operates on a substantial scale. The price-to-earnings ratio of 28.94 indicates a premium valuation, reflecting market confidence in its growth prospects. The forward P/E of 20.16 suggests expectations of continued earnings expansion, supported by a price-to-sales ratio of 3.84, highlighting strong revenue generation capabilities.

Strategically, Haleons global reach across over 100 countries is a significant asset, allowing the company to navigate diverse market dynamics effectively. Their robust distribution network and brand equity serve as formidable barriers to entry, protecting their market position. However, investors should remain vigilant about the companys debt levels and monitor the success of their R&D pipeline, crucial for sustaining long-term growth in a competitive landscape.

In conclusion, Haleons diverse product range, strong brand portfolio, and global presence position it as a resilient player in the consumer healthcare sector. Investors and fund managers would benefit from closely tracking Haleons ability to innovate and manage its financial leverage as it strives to maintain its leadership in a dynamic market environment.

Additional Sources for HLN Stock

HLN Stock Overview

Market Cap in USD 43,184m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC Sub-Industry Biotechnology
IPO / Inception 2022-07-22

HLN Stock Ratings

Growth 5y 63.4%
Fundamental 24.0%
Dividend 43.2%
Rel. Strength Industry 24
Analysts 4/5
Fair Price Momentum 9.99 USD
Fair Price DCF 9.01 USD

HLN Dividends

Dividend Yield 12m 1.57%
Yield on Cost 5y 2.16%
Annual Growth 5y 22.87%
Payout Consistency 100.0%

HLN Growth Ratios

Growth Correlation 3m -6.2%
Growth Correlation 12m 72%
Growth Correlation 5y 86.7%
CAGR 5y 13.03%
CAGR/Mean DD 5y 1.87
Sharpe Ratio 12m 1.03
Alpha 16.05
Beta 0.17
Volatility 16.10%
Current Volume 9754.7k
Average Volume 20d 9854.4k
What is the price of HLN stocks?
As of February 19, 2025, the stock is trading at USD 9.99 with a total of 9,754,740 shares traded.
Over the past week, the price has changed by +1.42%, over one month by +8.12%, over three months by +5.94% and over the past year by +22.79%.
Is Haleon a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Haleon is currently (February 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 24.04 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HLN as of February 2025 is 9.99. This means that HLN is currently overvalued and has a potential downside of 0%.
Is HLN a buy, sell or hold?
Haleon has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy HLN.
  • Strong Buy: 2
  • Buy: 0
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0
What are the forecast for HLN stock price target?
According to ValueRays Forecast Model, HLN Haleon will be worth about 10.9 in February 2026. The stock is currently trading at 9.99. This means that the stock has a potential upside of +9.51%.
Issuer Forecast Upside
Wallstreet Target Price 10.5 4.8%
Analysts Target Price 10.6 6.4%
ValueRay Target Price 10.9 9.5%